Extended Data Figure 1: Distribution of pHLIP to the renal system and lymph node metastases.

a, Intravenous injection of A750-pHLIP distributes to the (white arrow) kidneys and (blue arrow) tumour in a representative mir-155^LSLtTA subcutaneous flank model (n = 3); time points indicate hours after a single injection of A750-pHLIP. Previous reports have observed systemic distribution of pHLIP to kidneys in other mouse models¹⁵. Similarly, we speculate that the increased uptake of pHLIP peptide in the kidneys is due to excretion and increased acidity of renal tubule cells. Initially kidneys are highly enriched for pHLIP, which is gradually excreted while pHLIP shows a more steady accumulation in the tumour. b, Representative example showing A750-pHLIP distribution to the (white arrow) bladder and (yellow arrow) enlarged axillary lymph node 36 h after intravenous administration into mir-155^LSLtTA mice with lymphadenopathy (n = 3). c, In addition to distributing to the (white arrow) primary mir-155^LSLtTA flank tumour and (red arrow) kidneys, A750-pHLIP distributes to (black arrows) enlarged lymph nodes that resulted from metastatic spread; intravital fluorescence of A750-pHLIP was detected 48 h after intravenous injection into nude transplant mice with conspicuous lymphadenopathy (a representative animal from n = 3 is shown).